Research
Hormonal
Both doses of tirzepatide (10 mg and 15 mg) showed significantly greater reductions in predicted diabetes risk compared to placebo.
Practitioners may consider the effectiveness of tirzepatide over placebo in reducing diabetes risk.
StrongSupportsmedium confidence
The difference in LS mean risk change from baseline to week 52 was significant between both tirzepatide 10 mg (-3.2%, 95% confidence interval [CI]: -4.2%, -2.2%) and 15 mg (-3.4%, 95% CI: -4.4%, -2.4%) and placebo.
Why this rating
Based on the randomized controlled trial design of the SURMOUNT-CN trial.
Source
Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of <scp>SURMOUNT</scp> ‐ <scp>CN</scp> trial
Lin Zhao et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16439
other · n=169Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →